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Abstract
Background: Older adults at the end of life are commonly prescribed multiple medications
which can lead to polypharmacy. Research has shown that optimizing medications through
targeted deprescribing reduces inappropriate medications, reduces adverse effects and improves
select outcomes. However, the impact of deprescribing remains uncertain--specifically whether
this intervention improves quality of life (QOL). Objective: Explore polypharmacy in older
adults at the end of life examining outcomes of deprescribing on the QOL. Methods: A
systematic literature search using Academic Search Premier, CINAHL, Medline, JSTOR and
Nursing and Allied Health Database was conducted between October 2020 to November 2020.
Select articles published between 2010-2020 were included in the review. Articles using any
design or setting were included in the analysis as long as they addressed interventions to reduce
polypharmacy among older adults at the end of life and the outcome of the study addressed
QOL. One reviewer independently reviewed articles for eligibility, evaluated article quality and
extracted key data within the subset of articles retained for analysis. Results: The findings were
inconsistent with regard to the effect of deprescribing on QOL in older adults at end of life.
Conclusion: Further randomized controlled studies investigating the effects of reducing
polypharmacy on QOL in older adults at the end of life are needed to determine the impact of
reducing polypharmacy.
Keywords: older adults, end of life, quality of life, deprescribing, inappropriate medications,
outcomes
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Reducing Polypharmacy in Older Adults at the End of Life:
The Outcome on Quality of Life
The term polypharmacy is defined by the World Health Organization as “the
administration of many drugs at the same time or the administration of an excessive number of
drugs” and is a common occurrence in older adults (Schenker et al., 2019; Leblanc et al., 2015).
There is not an exact number of medications that has been specified to define the term
polypharmacy, however, numerous publications have defined polypharmacy as the use of more
than four to five medications at one time (Kierner et al., 2016). At the end of life, polypharmacy
is particularly burdensome as patients accumulate medications and experience an increasing risk
for being prescribed inappropriate medications (Schenker et al., 2019). Patients tend to be
prescribed medications to treat symptoms at the end of life in addition to the medications used to
prevent age related diseases and control comorbidities that may not be life threatening (Schenker
et al., 2019). These medications may carry harmful adverse effects, drug to drug interactions, pill
burden, and are costly (Schenker et al., 2019). A higher symptom burden has been associated
with poor health outcomes such as reduced quality of life (QOL), adverse drug reactions, falls,
hospitalization and mortality (Shrestha et al., 2020). There is evidence that suggests that with a
diagnosis of a limited life disease (LLD) or limited life expectancy (LLE), a reduction of
unnecessary or inappropriate medications is favored (Shrestha et al., 2020). At this point, the
primary focus should be on enhancing QOL including symptom control (Curtin et al., 2020;
Gardner, 2019; Lindsay et al., 2014). This literature review will explore polypharmacy, the
impact that deprescribing has on QOL in older adults at end of life, and provide
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recommendations for primary care providers on education, policy, research, and best practices
for deprescribing in older adults at end of life.
Background
Polypharmacy is a widespread phenomenon at the end-of-life care in settings such as
palliative care and hospice (Kierner et al., 2016). In a study conducted in the United States that
examined over 4000 patients in hospice, if was found that patients had been prescribed an
average of 15 medications at any one time (LeBlanc et al., 2015). Over 350 of these patients had
been prescribed 30 or more medications (LeBlanc et al., 2015). An average of 7.9 medications
were prescribed “as needed” and 8.3 medications were regularly scheduled (LeBlanc et al.,
2015). This study reveals the troubling occurrence of polypharmacy at end of life. Many
medications that are prescribed are to prevent disease where in these circumstances, the life
expectancy is limited (Schenker et al., 2019). Many of these patients at end of life have comorbidities that can increase risk of medication side effects and medications that are
administered at the end of life for symptom management carry significant side effects (Schenker
et al., 2019).
According to Gardner (2019), deprescribing is a recommended intervention to decrease
potentially inappropriate or unnecessary medications and reduce the harms of these medications.
Deprescribing is defined as a process of screening, identifying, and discontinuing medications
when the harm outweighs the benefits within the parameters of goals of care, treatment targets,
and patient’s remaining life expectancy (Lindsay et al., 2013). Screening for polypharmacy and
determining which medications are potentially no longer appropriate pose challenges for
providers (LeBlanc et al., 2015). Using evidence-based guidelines can help guide the clinician
with deprescribing decisions (Schenker et al., 2019). Deprescribing interventions have been
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shown to improve medication appropriateness and has the potential for mortality reduction and
cost savings (Shrestha et al., 2020). Unfortunately, the evidence associated with the benefits of
deprescribing has not been directly correlated with an improvement in QOL (Shrestha et al.,
2020). This literature review aims to answer the clinical question, Can reducing polypharmacy
for older adults at end of life improve QOL? The purpose is to advance understanding of the
impact of reducing polypharmacy at end of life and further guide evidence-based interventions
for primary care providers to address the phenomenon of polypharmacy and to achieve a better
QOL for patients at the end of life.
Answering this practice question is of clinical significance for advanced practice
providers and patients alike. Research on this topic suggests that primary care providers are open
to deprescribing but are reluctant to do so (Curtin et al., 2020). If consistent, rigorous evidence
exists regarding the benefits of deprescribing outweighing the risks associated with
polypharmacy, this will provide further support for the primary care provider to engage in
conversations with patients promptly at the end of life to reduce inappropriate or non-beneficial
medications.
Methods
An extensive literature search was completed on 11/13/20 with the assistance of a
librarian from Minnesota State University, Mankato. The following databases were searched
including Academic Search Premier, CINAHL, Medline, JSTOR and Nursing and Allied Health
Database. Terms used in the search include deprescribe, polypharmacy, reducing medication,
quality of life, end of life, palliative, hospice, and life limiting disease. Limits applied to the
database searches included studies published between 2010-2020, full text availability, scholarly
peer-reviewed journals, and English language. Within each database, the number of article ‘hits’
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received for every keyword search were recorded (see Table 2 of the appendix). The articles that
were relevant to the clinical question were marked for full review. After eliminating duplicate
articles, the review of article titles and abstracts yielded 31 studies to further determine inclusion
or exclusion based on select criteria. Nine articles met the inclusion criteria. All unique hits after
scanning and eliminating titles and bibliographic review are indicated in bold in Table 2 of the
appendix. These hits are subsequently included in Table 3 of the appendix for specific inclusion
or exclusion.
Inclusion and Exclusion Criteria
The nine articles that met inclusion criteria directly address: (a) older adults (aged > 65
years), (b) participant needed to be considered at end of life, receiving palliative care or hospice,
limited life illness, or limited life expectancy, (c) deprescribing intervention, (d) QOL and health
related outcomes of deprescribing. The articles were excluded if they (a) age < 65 years of age,
(b) did not fall under the criteria of end of life, (c) did not involve the intervention of
deprescribing, (d) QOL and health related outcomes of deprescribing were not addressed. Refer
to the appendix in Table 3 for the articles that were reviewed and the rationale for inclusion and
exclusion are provided for each reference.
A total of 863 articles were identified through electronic search databases. After
removing duplicates and searching keywords used within abstracts, 31 articles were reviewed
from which nine articles were included within this literature review (Table 4). Data from the
articles included were extracted independently by one author and inserted into a pre-designed
template for interpretation and synthesis of the literature review (Table 4). Data abstracted
included: authors, year of publication, study purpose, population, sample size, setting, type of
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design and level of evidence, variable/instruments, and intervention. Outcome data were
summarized for each study.
Summary of the Findings
Within the review of literature, the highest level of evidence within the nine articles in
this review was level I (LeBlanc et al., 2015; Lindsay et al., 2014; Shrestha et al., 2020); other
evidence was level II, IV and V (Curtin et al., 2020; Gardner, 2019; Kierner et al., 2016; Kutner
et al., 2015; Parker et al., 2019; Schenker et al., 2019). Two of the three systematic reviews
addressed polypharmacy in advanced cancer and the outcomes of deprescribing (LeBlanc et al.,
2015; Lindsay et al., 2014). The other systematic review investigated the evidence surrounding
the outcome of deprescribing in patients with limited life expectancy and life limiting illness
(Shrestha et al., 2020). The level II articles encompassed three randomized control studies that
examined the outcomes from deprescribing (Curtin et al., 2020; Kutner et al., 2015; Parker et al.,
2019). The other articles include a retrospective study examining polypharmacy at the end of life
and a secondary analysis of the association of polypharmacy, symptom burden, and QOL
(Kierner et al., 2016; Schenker et al., 2019). An expert opinion was included that addressed
deprescribing at the end of life (Gardner, 2019).
Polypharmacy
Polypharmacy has been defined as the use of several medications, the underuse of
medications when the indicated medication is not used, or when there is a duplication of
medications (Kierner et al., 2016). Although the number of medications has not been identified
for polypharmacy, there is evidence that negative outcomes are associated with polypharmacy
even when taking as few as four medications at a given time (LeBlanc et al., 2015). The
prevalence of polypharmacy is a well-recognized problem in older patients and is associated with
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comorbid conditions as well as cancer (LeBlanc et al., 2015). According to LeBlanc et al. (2017),
older patients with cancer received more polypharmacy than younger patients (2015). For
example, nursing home residents are prescribed an abundance of medications and are at an
increased risk of adverse drug events (Curtin et al., 2020). Many of the residents in nursing
homes have limited life expectancy (average of time until death is five months) therefore many
do not live long enough to reap the benefits of their prescribed medications (Curtin et al., 2020).
Palliative care patients experience polypharmacy and when they suffer worsening
symptoms, they are prescribed additional medications to treat these symptoms (Kierner et al.,
2016; LeBlanc et al., 2015; Schenker et al., 2019;). This is referred as the “prescribing cascade”
where medication related adverse effects leads to additional medications prescribed (Schenker et
al., 2019). Schenker et al. (2019) examined the associations between polypharmacy, symptom
burden, and QOL in patients with a life limiting illness. They discovered that the results are
bidirectional; polypharmacy was associated with higher symptom burden and lower QOL
(Schenker et al., 2019). In contrast, a different way to view the data is patients with poorer QOL
are more ill, have more symptoms, which increases the number of medications they require,
attributing to polypharmacy (Schenker et al., 2020). The authors suggested areas for future
research to include a focus on developing and evaluating deprescribing strategies to reduce
inappropriate medications in patients at the end of life (Schenker et al., 2020).
Polypharmacy is shown to occur even days before death in advanced cancer patients
(Kierner et al., 2016). Kierner et al. (2016) completed a retrospective study, reviewing charts of
100 patients that had died due to advanced cancer. The study revealed that nine days before
death, patients were prescribed 11 medications (Kierner et al., 2016). Although this number
decreased significantly towards the day of death, patients were still prescribed a median of 6.5
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drugs on their last day (Kierner et al., 2016). Due to an increase in anticholinergic and
serotonergic loads, polypharmacy can be extremely dangerous in patients at the end of life
(LeBlanc et al., 2015). For example, research conducted in hospice settings demonstrated that
dying patients experience an anticholinergic burden that is associated with adverse effects such
as poor mental concentration, reduced QOL, and worsening physical function (LeBlanc et al.,
2015).
Potentially Inappropriate Medications
Published studies have reported harm with even one unnecessary or inappropriate
medication (LeBlanc et al., 2015). Furthermore, there has been an association with PIM and
health outcomes including reduced QOL, falls, hospitalization and even mortality. Despite these
known risks, patients continue to receive preventative medications including statins,
antihypertensives, antiplatelets, antidiabetics, antiulcer, vitamins and mineral supplements
(Shrestha et al., 2020). LeBlanc et al. (2015) reported that in a study of 87 patients with
advanced cancer in an ambulatory setting, 21 (24%) patients were taking at least one
unnecessary drug. This was often noted when a provider did not reconcile their medication list
(LeBlanc et al., 2015). This helps support the need for interventions, such as a full medication
reconciliation in order to discontinue unnecessary medications (LeBlanc et al., 2015).
Interventions to Reduce Polypharmacy
Schenker et al. (2019) and Gardner (2019) suggest that clinicians who work with
advanced, life limited illnesses should learn targeted strategies for deprescribing, and this should
be completed routinely (Schenker et al., 2019). A collaboration between provider and patient
preference should assist with making deprescribing decisions, especially if the risk and benefits
of the medication is unknown (Schenker et al., 2019; Gardner, 2019). Deprescribing is
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considered an intervention that is completed by cautiously tapering and withdrawing medications
utilizing approved tools or algorithms with a multidisciplinary approach led by a clinician or
pharmacist (Shrestha et al., 2020).
Within the literature, there were several guidelines recommended for use when
considering a deprescribing initiative. Lindsay et al (2014) reported that most of the guidelines to
identify PIMs in the older adult medicine were mostly based on Beers Criteria or Screening Tool
of Older Person’s Prescriptions (STOPP)/Screening Tool to Alert doctors to Right Treatment
(START). The Beers Criteria provides a concise list of medications, dosages, and duration of
therapy that should be avoided in patients over the age of 65 years and older (Lindsay et al.,
2014). The STOPP Criteria consists of 65 indicators that are associated with drug-to-drug
interactions, drug to disease interactions, and duplication of therapy (Lindsay et al., 2014). A
benefit of these guidelines is that PIM can be identified effectively by novice or experienced
clinician or pharmacists (Lindsay et al., 2014). Unfortunately, there are limitations for using
these guidelines in palliative care. Patients in palliative care often suffer from distressing
symptoms and receive appropriate medications to treat those symptoms which are deemed
inappropriate according to these deprescribing guidelines (Lindsay et al., 2014). In addition,
there is the complexity factor to consider with patients receiving palliative care (Lindsay et al.,
2014; Curtin et al., 2020). Within this population at the end of life, physiology changes such as
body mass, metabolism, and elimination can affect the pharmacokinetics and pharmacodynamics
of any medication administered (Shrestha et al., 2020) and cause a potential for drug related
toxicity, drug interactions and the patient response to the medication (Gardner, 2019).
There are practice guidelines that are being explored for use in palliative care such as the
Good Palliative Geriatric Practice guideline (GP-GP) and 5-point algorithm (Lindsay et al.,
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2014). The GP-GP has targeted statements that question if the medication is appropriate (Lindsay
et al., 2014). The 5-point algorithm considers medications that provide a limited benefit for
patients at end of life (Lindsay et al., 2014). However, there are limitations to these guidelines, as
it requires skilled clinicians to use the algorithm (Lindsay et al., 2014). Some of the criteria
within these guidelines are broad and rely heavily on an experienced clinician’s assessment
(Lindsay et al., 2014). For example, the GP-GP algorithm has two criteria for discontinuing a
medication are “Indication seems valid and relevant in this patient’s age group and disability
level” and “Do the known possible adverse reactions of the drug outweigh possible benefit in
old, disabled patients” (Lindsey et al., 2014, p. 1116). Lindsey et al. (2014) recommended for
future studies are warranted to establish clear guidelines for identifying PIMs in palliative cancer
patients and outcomes of discontinuing PIMs for these patients.
The balance of discontinuing medications during end of life can be challenging (Gardner,
2019). Deprescribing medication too soon can be viewed as negligent or causing harm but if too
late, this may result in inappropriate treatment and cause additional stress on the patient
(Gardner, 2019). Another consideration at the end of life is that the patient is no longer
benefiting from the medication to preserve life (Gardner, 2019). Curtin et al. (2020) reported that
there is a functional decline in patients transferred to the nursing home from the hospital setting
and this provides an opportune time to conduct a medication review with a focus on QOL rather
than focusing on long term prevention strategies on chronic disease management (Curtin et al.,
2020).
LeBlanc et al. (2015) reported in a systematic review that in an ambulatory study, an
interdisciplinary team approach to a comprehensive review was conducted and patients were
noted to be resistant to accepting the recommendations for reductions in their drug regimens.
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This suggests that there are concerns from patients and families for accepting these deprescribing
strategies (LeBlanc et al., 2015). The study also mentioned concerns about providers accepting
these strategies. In fact, Curtin et al. (2020) highlighted evidence that hospital physicians do not
take the opportunity to deprescribe in frail multimorbid older people due to “fear of negative
consequences such as that symptoms would return, clinical deterioration, litigation, or increased
workload” (Curtin et al., 2020, p. 739). Further investigation is warranted on successful ways to
communicate the goals of these interventions to reduce polypharmacy for patients, family
members and prescribers (LeBlanc et al., 2015).
Despite clear guidelines for polypharmacy in patients with advanced cancer or end of life,
LeBlanc et al., (2015) recommend that clinicians be aware of the issue and complete an informal
screening for polypharmacy, specifically in elderly frail patients that are at high-risk to develop
an adverse drug reaction. Greater attention to polypharmacy in patients with advanced cancer
and end of life would ultimately lead to reductions in adverse drug events, cost, and even
improvements in QOL (LeBlanc et al., 2015; Gardner, 2019). Lindsay et al. (2014) and LeBlanc
et al. (2015) suggest that further research is necessary to establish guidelines for identification of
PIMs in end of life and palliative care.
Non-Essential and Essential Medications
Gardner (2019) provided an expert opinion including recommendations that
conversations surrounding deprescribing at the end of life should be patient-centered and
initiated early (Gardner, 2019). The author reported that within end of life medication
management, prescriptions need to be classified into non-essential and essential groups (Gardner,
2019). Non-essential medications would be considered those medications prescribed to manage
underlying conditions where there is no chance to recover, and the administration of the
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medication would prolong the dying process as well as serve no therapeutic purpose (Gardner,
2019). Essential medications manage symptoms such as breathlessness, pain, and nausea
(Gardner, 2019). When a patient is no longer able to swallow, alternative routes of
administration should be considered (Gardner, 2019). Gardner (2019) also suggests that at end of
life, each medication should be evaluated for the route, time of administration and risk versus
symptom management.
Outcomes of Deprescribing
Reduction of Polypharmacy
Gardner (2019) reports that deprescribing enhances the patient’s QOL by ultimately
reducing the drug burden without compromising patient safety or well-being (Curtin et al.,
2020). Each study approached deprescribing differently, but data supports that deprescribing
interventions can reduce inappropriate medications. Shrestha et al. (2019), in their systematic
review revealed a reduction in the number of medications after deprescribing intervention in six
of the nine studies, despite the use of varying deprescribing tools. Whereas in a randomized
controlled study by Curtin et al. (2020), a protocol referred to as “STOPPFrail” guided the
deprescribing plan and was used in older people approaching end of life. A significant reduction
in polypharmacy was reported (Curtin et al., 2020). The results wer that almost one in four
medications in polypharmacy patients were discontinued (Curtin et al., 2020). The primary
indication for deprescribing a medication included not having a valid clinical indication for the
patient to take the medication (Curtin et al., 2020). This supports routinely reviewing whether a
medication is linked to a diagnosis or a symptom that is active or reoccurring during formal
medication reviews in older patients at end of life (Curtin et al., 2020).
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In a systematic review of 21 articles, LeBlanc et al. (2015) found the data reflects the
effectiveness to reduce polypharmacy by using interventions to identify potential inappropriate
medications. For example, the Beers criteria was applied to an oncology acute unit of elders,
which showed that 32% of patients were prescribed nine or more medications and 42 of the 51
recommendations were implemented (LeBlanc et al., 2015). A drug error was corrected in one of
every eight patients that could have or did result in an adverse drug event (LeBlanc et al., 2015).
The only study that did not demonstrate a decrease in polypharmacy was an intervention study
with older adults diagnosed with chronic kidney disease. A medication review using the
STOPP/START criteria revealed there was no improvement in reduction of PIMs although the
low impact of this study may be due to the judgement left to the attending physician, differences
in populations, and the length of time period (Parker et al., 2019).
Mortality
The US Palliative Care Research Cooperative Group conducted a randomized control
study to assess the safety and clinical impact of discontinuing statin medications for patients in a
palliative care setting (Kutner et al., 2015). Participants that were eligible to participate included
those with a life expectancy between a month and a year and were taking a statin for at least
three months for primary and secondary prevention of cardiovascular events (Kutner et al.,
2015). The study reported that survival 60-days after the intervention did not differ significantly
between the groups and suggested that there is no immediate or short-term harm (Kutner et al.,
2015). With these results, it appears that it is safe to stop statin therapy when there is high risk
for death with the next six to 12 months (Kutner et al., 2015). Kutner et al. (2015) reported that it
is possible that when discontinuing statins, this will decrease adverse effects and ultimately
decrease medications that may have been needed to treat the possible adverse effects.
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A study that was conducted by Curtin et al. (2020) found that there was no statistically
significant difference between the intervention and control groups on mortality. The intervention
consisted of applying STOPPFrail protocol to the medication regimens of older adults with
limited life expectancy within two hospitals in Ireland (Curtin et al., 2020). Measurement of the
intervention effect on patient health outcomes such as mortality was difficult to determine due to
the small sample size (Curtin et al., 2020). A study by LeBlanc et al (2015) reported that using a
GP-GP algorithm resulted in medication reduction and a global improvement in health. Mortality
rate was reduced after one year follow up with a 21% death rate in the intervention group
compared to 45% death rate in the control group (LeBlanc et al., 2015). It is important to note
that this study’s participants were community dwelling adults with a mean age over 80 years old
and those with LLE were excluded (LeBlanc et al., 2015). In a systematic review completed by
Shestha et al. (2020), two random controlled trials (RCTs) and a quasi-experimental study
reported on mortality and/or survival. Shrestha et al. (2020) discussed that the evidence within
the literature on the effects of deprescribing on mortality is conflicting. The overall reduction in
the percentage of mortality was found in the residential aged care facility and hospitals but there
was no significant difference between intervention group and control group assessed at 6 and 12
months after the intervention (Shrestha et al., 2020). Shrestha et al. (2020) suggested that
deprescribing is safe and does not quicken death in patients at the end of life care (Shrestha et al.,
2020).
Cost
Many studies have analyzed costs and shown that reducing polypharmacy lessens the
burden on healthcare costs (Lindsay et al., 2014; Shrestha et al., 2020). In a study conducted by
Kutner et al. (2015), a cost savings with the discontinuation of the statin was found to be $3.37
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per day per patient and $716 per patient during the course of the study. In another study, the
mean change of monthly medication costs at the 3-month follow up after deprescribing was
$74.97 in the intervention group compared to $13.22 in the control group (Curtin et al., 2020).
Within a systematic review of outcomes after deprescribing at the end of life, Shrestha et al.
(2020) reported in a pre-experimental pre-post study where there was an overall cost reduction
and predicted healthcare costs could be reduced by $4,2827.27 per person.
Clinical Outcomes
The primary outcome measure of this review was to examine the effect of deprescribing
on quality of life. However, many of the studies included in this review measured other clinical
outcomes. Three randomized controlled trials and a systematic review reported on other health
outcomes besides quality of life, mortality, and costs. Most studies found no differences in
clinical outcomes. The clinical outcomes that were measured after deprescribing intervention
included unscheduled hospital presentations, number of falls, medication adherence,
performance status, symptoms, sleep quality, bowel function, cognitive function, physical
function, and general health, performance between the intervention and control groups. Only the
systematic review by Shrestha et al. (2020) identified two studies that reported an impact on
clinical outcomes. A randomized controlled study reported a reduction in the number of falls at
12 months in the intervention group but not in the control group (Shrestha et al., 2020). In
another randomized controlled study that examined clinical outcomes after deprescribing as the
intervention reported no significant difference in the sleep quality, bowel function, cognitive
function, physical function, and general health, performance between the intervention and
control groups however although not the results were not significant there was an improvement
in sleep quality and bowel function noted (Shrestha et al., 2020).
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All three randomized controlled studies measured clinical outcomes as secondary
outcomes. Curtin et al., (2020) applied the STOPPFrail protocol to medication regimens in older
adults with frailty and examined outcomes including unscheduled hospital presentations and
falls. The study detected no impact on these secondary outcomes (Curtin et al., 2020). The
limitations of the study were that the trial was most likely underpowered to detect the differences
of outcomes (Curtin et al., 2020). Parker et al. (2019) examined medication adherence as a
clinical outcome and also found no detectable impact of the intervention on medication
adherence. It should be noted that the adherence was high at baseline which supports previous
studies results reporting that in older adults, medication adherence is high (Parker et al., 2019).
Curtin et al. (2020) and Shrestha et al (2020) recommended a larger trial be conducted with
greater statistical capabilities to determine clinical outcomes of deprescribing interventions
within patients at end of life
Quality of Life. Many of the articles reviewed hypothesized that by reducing the burden
of polypharmacy at end of life, it would lead to reductions in adverse drug events, cost and
potentially improve QOL (LeBlanc et al., 2015). Within the literature reviewed, there were
varying results of deprescribing on QOL and a variety of tools used to measure QOL. For
example, in the US Palliative Care Research Cooperative Group that promoted the unnecessary
statin use in the last year of life assessed QOL using the McGill QOL. The McGill QOL
instrument is a questionnaire that reflects a single-item overall QOL score and subscale scores
(Kutner et al., 2015). Higher scores indicate better QOL and range from 0 to 10 (Kutner et al.,
2015). The total McGill QOL was higher in the statin discontinuation group, however the single
question addressing overall QOL showed no significant difference between the intervention
group discontinuing stating therapy and control group (Kutner et al., 2015). Kutner et al. (2015)
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concluded that for patients seeking to reduce pill burden and comfort goals, physicians may
promote the discontinuation of statins without affecting survival or QOL. In a study conducted
by Curtin et al. (2020), QOL was measured using two different assessment tools: Quality of Life
in Alzheimer’s dementia (QUALIDEM), an instrument completed by the healthcare team and
assesses QOL across all domains for patients at all stages of dementia and the Index of
Capability for Older Adults (ICECAP-O), a questionnaire that is a broad measure of QOL
covering five capabilities (attachment, security, role, enjoyment, and control). The study found
that QOL deteriorated significantly in the intervention group that received a deprescribing
method using the STOPPFrail criteria and control group at both the baseline and 3-monthfollow
up but the difference was not statistically significant within scores (Curtin et al., 2020). A
randomized controlled trial published by Parker et al. (2019) used the STOPP/START criteria for
deprescribing medications in elderly patients with chronic kidney disease (CKD) to detect
inappropriate medications after 6 months follow-up and used the 12 item Short-Form Health
Survey to assess health-related quality of life (HRQoL). The 12-item Short-Form Health Survey
is self-administered and is validated for use in multiple patient groups including CKD patients to
assess the physical and mental health status of patients (Parker et al., 2019). The findings
revealed that there was no significant impact on HRQoL scores between the intervention and
control groups (Parker et al., 2019). The findings of HRQoL scores within this study were low
and is consistent with those found in other patients with CKD (Parker et al., 2019).
In a systematic review completed by Shrestha et al. (2020), the findings revealed that
deprescribing had the potential for mortality reduction and cost savings but the impact on QOL
and falls were not consistent. A measure that matters most to older patients with LLI and LLE
and to their family members is QOL. This systematic review included two RCTs. In one study
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using the Quality of Life in Alzheimer’s Disease (QOLAD) tool with a high percentage of
participants with dementia, the QOL was shown to be reduced. In the other study with a higher
number of participants with cancer, the results of the McGill QOL questionnaire found that QOL
improved.
Strengths and Limitations of This Review
This literature review identified numerous articles on the incidence of polypharmacy, the
effectiveness of deprescribing to lower drug burden, along with the secondary outcomes of
deprescribing medications, however there were limited interventional studies that investigated
QOL as the primary outcome when deprescribing medications at the end of life. This author
searched numerous databases to include all different types of studies including systematic
reviews which have higher level of evidence. The research included within this article has
considerable heterogeneity in regard to the participant population and setting, deprescribing
measurement tools utilized, and QOL measurement tools used within the studies.
This review was not without limitations. A limitation of this review was the
inclusion/exclusion criteria. Due to the lack of interventional studies completed on assessing
QOL, systematic reviews and an expert opinion were included. There is an abundance of
research addressing deprescribing and the impact on QOL in older adults however terminal ill is
an exclusion criterion in the majority of articles. There are few retrospective studies that are
included within this review that may have allowed for overestimated quantities of medications
because the patients that were experiencing a variety of unexpected complications and need
additional treatment were included within those studies. Although it should be mentioned that if
the study was completed in real time, there might have been an influence on the prescribing
behaviors (Kierner et al., 2016).
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Gaps in Literature
The review of the literature included three interventional studies addressing clinical
impact including QOL when deprescribing at end of life. There are systematic reviews that
address clinical outcomes that either directly address patients with cancer or clinical outcomes
within a variation of limiting life illnesses. The systematic reviews that were included
encompassing a cancer diagnosis highlight the vulnerability of this population and the lack of
descriptive studies on the impact of deprescribing at end of life including older adults but also for
younger adults.
There are previous studies that have been conducted to evaluate the clinical impact of
deprescribing (including QOL) of older adults, but patients with limited life expectancy are
generally excluded. Hypothetically, these findings in older adults could be transferrable to
patients at end of life, however this would be an untested and unvalidated assumption. Within
these three interventional studies, the primary focus was not on the clinical outcomes; rather they
were investigating the impact of deprescribing on polypharmacy or on potential inappropriate
medications. More evidence is needed on the clinical impact of deprescribing and the effect on
other areas including physical, cognitive, and psychosocial health status (Shrestha et al., 2020).
In addition, the studies included for review within this manuscript contain a variety of
instruments to measure QOL. It would be important to be consistent with the review to evaluate
the validity, reliability and impact of one measurement tool or compare measurement tools for
validity of data retrieved.
Discussion
This literature search sought to explore polypharmacy and the impact that deprescribing
has on QOL in older patients at the end of life. It was evident that polypharmacy exists in
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patients nearing end of life and as death nears, the number of medications typically increase
(LeBlanc et al., 2015; Lindsay et al., 2014; Kierner et al., 2016; Schenker et al., 2019; Shrestha
et al., 2020). In randomized controlled settings, deprescribing interventions were carried out and
there were significant reductions in potentially inappropriate prescriptions (Curtin et al., 2020;
Shrestha et al., 2020). Additionally, the findings regarding the impact of deprescribing on QOL
were inconsistent. There were limited studies addressing the topic and the studies that were
identified did not have the clinical question as the primary outcome of the study. This made it
challenging to answer the clinical question posed. Based on the three randomized control studies
that were identified within the literature search, only one of them found that deprescribing was
associated with a significant improvement of QOL whereas the other two studies found no
significant change between groups. Within the systematic review by Shrestha et al. (2020), one
of the studies found no significant improvement in QOL and the other study found a significant
improvement on QOL. It should be noted that the study that found a significant improvement on
QOL within the systematic review by Shrestha et al. (2020) was the study conducted by Kutner
et al. (2015) which was a randomized controlled study that was included within this current
review.
This is the first review of literature examining the effect of deprescribing on QOL at the
end of life. A prior review of 12 studies conducted by Pruskowski et al (2019) investigated the
impact of deprescribing on QOL and secondary outcomes including satisfaction with care and
emergency department visits and hospitalizations on older adults and older persons with life
limiting conditions were included. The results were similar in that there was a reduction on at
least one medication deprescribed in ten of the studies and found no difference in QOL of two
studies that measured this outcome (Pruskowski et al., 2019). The focus of this review is on
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patients at the end of life because they experience a high medication burden with a limited life
expectancy; medications administered should be given only if it improves QOL and symptom
control (Lindsay et al., 2014).
There are possible explanations for the inconsistency observed in the studies with the
effect of deprescribing on QOL. There were different QOL measurement tools that were used
within the studies that may affected results as mentioned by Shrestha et al. (2020). Within each
of the studies, participants were reported to be at the end of life, but they varied in medical
conditions. Another consideration for a variation in results is the length of the study. The time
length of the studies varied from three months to six months. The study that had a three-month
follow up reported that the QOL dropped but it was not statistically significant (Curtin et al.,
2020) whereas in a different with a six month follow up reported an increase in QOL. One could
ponder that the reason for a drop may be due to withdrawal symptoms or the progression in the
end of life. It is also uncertain if a patient’s QOL would improve in a short time or if a longer
duration is needed to see improvements. In the statin discontinuation trial where an increase in
QOL was reported, the difference with this study compared to the others is that it was a specific
medication that was discontinued (Kutner et al., 2015). The patient had agreed to have this
medication removed and was there an increase in QOL reported based on their own decision.
Lastly, another way to view the results that showed no significant change in QOL is that the
removal of the medication did not harm the patient.
In addition to investigating polypharmacy and the impact of deprescribing on QOL, there
were several other clinical outcomes investigated within the studies such as medication
adherence, unscheduled hospital presentations, falls, monthly medication costs, and mortality.
Although the findings associated with clinical outcomes varied, cost savings were reported. In
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addition to clinical outcomes being investigated, a study included within this review examined
the associations between polypharmacy, symptom burden, and QOL (Schenker et al., 2019). This
study provides a link between polypharmacy and association with higher symptom burden and
worse QOL for patients at the end of life (Schenker et al., 2019). This builds upon the growing
body of research related to deprescribing and using this association when developing and
evaluating deprescribing strategies could improve patient’s outcomes (Schenker et al., 2019).
Implications for future
Clinical practice recommendations
Primary care providers working with patients at end of life should take personal
responsibility to educate themselves on the targeted strategies to deprescribing and should
include this intervention routinely with patients at end of life (Schenker et al., 2019). All
discussions should be patient centered and include advance care planning in the process to avoid
any misinterpretation of actions (Gardner, 2019). Although there is not a standard guideline for
deprescribing at the end of life, there are many evidence-based guidelines available to assist with
making these decisions for deprescribing (Schenker et al., 2019). Each medication should be
reviewed and evaluated for the route, time of administration, adverse effects, drug-drug
interactions, benefit to continuing medication, risk of deprescribing, and symptom management
(Gardner, 2019). It is important for clinicians to have discussions on medication management
promptly and repeatedly throughout the dying process making sure that the patient’s preferences
are included (Gardner, 2019).
Recommendations for research
This literature review identified many opportunities for future research. Although
polypharmacy is well reported in older adult patients, the outcomes and effects are less clear for
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patients at end of life (LeBlanc et al., 2015). In addition, a standardized measure and definition
of polypharmacy that are appropriate in this unique population, for example patients with
advanced cancer (LeBlanc et al., 2015) require further exploration. There were limited
interventional studies that examined the impact of deprescribing on QOL and the studies that
were completed investigated QOL as a secondary outcome rather than the primary outcome.
Further studies could focus on examining the impact on QOL when using a deprescribing tool
(Parker et al., 2019). Curtin et al. (2020) suggested that a larger scale multicenter trial with
higher statistical power is necessary to provide evidence for clinicians that deprescribing
medications can be achieved without jeopardizing health outcomes. The study of the
discontinuation of a statin by Kutner et al. (2015) suggested that QOL could be improved.
Additional research is needed in identifying other medications in this population that they would
benefit from discontinuation (Kutner et al., 2015). A consensus in many of the articles was the
need for tested and implementable strategies to reduce polypharmacy for individual medications
and cumulative effects of medications prescribed (LeBlanc et al., 2015; Schenker et al., 2019;
Kierner et al., 2016). Another area of research identified was effective ways to communicate the
goals of reducing polypharmacy to patients, families, and even providers (LeBlanc et al., 2015).
Providing education to the patient on reasons for medications that should be discontinued will
increase their understanding and increase the patient’s participation in making decisions
(LeBlanc et al., 2015).
Education recommendations
Provider’s experience with addressing end of life care can vary and some avoid engaging
in these conversations surrounding discontinuing medications (Gardner, 2019). Each provider
may vary in their assessment of the importance and inappropriateness of medications (Curtin et
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al., 2020). In addition, there is fear for negative consequences of deprescribing such as
“symptom relapse, clinical deterioration, litigation, or increased workload” (Curtin et al., 2020,
p. 763). Many providers advocate to reduce drug burden at end of life but are unsure of the
medications to discontinue, when to discontinue, and uncertain if it is safe to discontinue (Kutner
et al., 2015). There is a great deal of research on when to start medication but there is a lack of
effort towards when to discontinue especially at end of life (LeBlanc et al., 2015). Education and
training programs can incorporate deprescribing into their curriculum standards for providers and
continuing education should be provided on an ongoing basis. As highlighted in the literature,
guidelines and evidence on the benefits to deprescribing would motivate primary care providers
and patients to routinely make those shared decisions surrounding the discontinuation of
medications.
Recommendations for policy
Many clinicians are hesitant to deprescribe for various reasons. Clinicians may be
reluctant to discontinue a medication if the patient is seeing a specialist that they believe are
overseeing the patient’s medications (Curtin et al., 2020). Curtin et al. (2020) highlighted a
barrier to deprescribing is time constraints. Providers may also be hesitant to discontinue
medications because their actions may be misinterpreted from the patient or family feeling that
they are giving up on the patient (Gardner, 2019). A systems approach to deprescribing could
address many of these reasons that prescribers may forgo deprescribing at end of life until it is
immediate when the patient is no longer able to swallow. There is a culture within our society
that considers medications to be valuable. There is also an ideation that if a patient has been on a
medication for a long time, they question why they would stop now. Deprescribing plans should
be discussed with a patient when prescribing the medication. A multidisciplinary approach to
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deprescribing interventions will lessen the burden on the primary care provider and also provide
a collaboration between healthcare professionals. These professionals include nurses,
pharmacists, primary care providers, and specialists. Another incentive to deprescribing is to add
reimbursement, therefore the primary care provider could schedule a visit to complete
deprescribing interventions.
Conclusion
Overall, there is a lack of research on examining the direct impact of deprescribing on
quality of life in older adults at the end of life. Although the deprescribing interventions resulted
in improvement of medication reduction, the impact on improving quality of life was not clear.
This was consistent with other clinical outcomes not found to be statistically significant; with the
exception of cost savings. These results do not undermine the need for discontinuing
inappropriate medications at the end of life. Primary care providers are involved with patient’s
advanced care planning at end of life and require evidence based deprescribing interventions that
consider preventative and symptom control to identify potentially inappropriate medications. In
addition, continued progress in education, practice, policy, and research on deprescribing at the
end of life will ultimately impact the QOL for this population.
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Appendix
Table 1
Database Search Description
Database (or Search
Engine)

Restrictions
Added to Search

Dates Included in
Database

Academic Search Premier

Full Text;
Scholarly (Peer
Reviewed); English
Language

2010-2020

CINAHL

Full Text; English
Language; Abstract
Available; Peer
Reviewed

2010-2020

MEDLINE

Full Text; English
Language

2010-2020

JSTOR

Full Text

2010-2020

Nursing and Allied Health
Database

Full Text; Peer
Reviewed; English
Language

2010-2020

General Subjects Covered by Database
The database offers information in nearly every area of
academic study, including arts, biology, chemistry,
computer sciences, ethnic studies, engineering,
language and linguistics, literature, medical sciences,
philosophy, physics, psychology, religion, social
sciences, and more.
Provides full text with comprehensive indexing of
nursing and allied health journals including
publications in nursing and allied health, consumer
health, alternative/complementary medicine,
biomedicine, and health sciences librarianship
Produced by the U.S. National Library of Medicine and
is widely recognized as the premier source for
citations, indexing, and abstracts of biomedical
literature. MEDLINE provides information relevant to
the fields of medicine, nursing, and dentistry, and it
also covers areas of life sciences, behavioral sciences,
chemical sciences, and bioengineering that are related
to health and biomedicine.
Journals in the social sciences, arts and humanities and
life sciences. Listed under philosophy database
Provides users with reliable healthcare information
covering nursing, nutrition, oncology, pediatric care,
pharmacology, public health, allied health, alternative
and complementary medicine, and much more.
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Table 2
Data Abstraction Process

Date of
Search

Key Words

11/13/20

"deprescrib*" or
"polypharmacy" or
"reducing medication"
AND “quality of life” or
“QOL" AND "end of
life" or "palliative" or
"hospice" or “life
limiting disease”
"deprescrib*" or
"polypharmacy" or
"reducing medication"
AND “quality of life” or
“QOL" AND "end of
life" or "palliative" or
"hospice" or “life
limiting disease”
-Abstract
"deprescrib*" or
"polypharmacy" or
"reducing medication"
AND “quality of life” or
“QOL" AND "end of
life" or "palliative" or
"hospice" or “life
limiting disease”
-Subject
Bibliography

Results in
Academic
Search
Premier
14

Results in
CINAHL

Results in
JSTOR

Results in
Medline

Results in
Nursing Allied
and Health

10

4

10

809

-

-

-

-

11

-

-

-

3

-

2

-

-

-

-

*BOLD = articles reviewed for match with systematic review inclusion criteria
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Table 3
Characteristics of Literature Included and Excluded
Reference
(Include the full reference here)
Alexa, I. D., & Pîslaru, A. I. (2017). When is time to consider
palliation in the general therapeutic plan in senior patients?
Paliatia: Journal of Palliative Care, 10(3), 8.
Briscoe, J., & Casarett, D. (2018). Medical Marijuana Use in
Older Adults. Journal of the American Geriatrics Society,
66(5), 859–863. https://doiorg.ezproxy.mnsu.edu/10.1111/jgs.15346
Chadwick, S. (2019). P-135 Evaluation of tolerability and
deprescribing of anti-fibrotics in pulmonary fibrosis (IPF)
patients. BMJ Supportive & Palliative Care, 9
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare2019-HUKNC.158
Cortis, L. J. (2017). A qualitative study to describe patientspecific factors that relate to clinical need for and potential to
benefit from a medication management service in palliative
care. Journal of Pharmacy Practice & Research, 47(1), 34–40.
https://doi-org.ezproxy.mnsu.edu/10.1002/jppr.1147
Curtin, D., Jennings, E., Daunt, R., Curtin, S., Randles, M.,
Gallagher, P., & O’Mahony, D. (2020). Deprescribing in Older
People Approaching End of Life: A Randomized Controlled
Trial Using STOPPFrail Criteria. Journal of the American
Geriatrics Society, 68(4), 762–769. https://doiorg.ezproxy.mnsu.edu/10.1111/jgs.16278
Development of a health-system palliative care clinical
pharmacist. (2017). American Journal of Health-System
Pharmacy, 74(1), e6–e8. https://doiorg.ezproxy.mnsu.edu/10.2146/ajhp160055
Economos, G., Lovell, N., Johnston, A., & Higginson, I. J.
(2020). What is the evidence for mirtazapine in treating
cancer-related symptomatology? A systematic review.
Supportive Care in Cancer, 28(4), 1597–1606. https://doiorg.ezproxy.mnsu.edu/10.1007/s00520-019-05229-7
Frechen, S., Zoeller, A., Ruberg, K., Voltz, R., & Gaertner, J.
(2012). Drug interactions in dying patients: An international
journal of medical toxicology and drug experience. Drug
Safety, 35(9), 745-758.
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.2165/11631280000000000-00000
Gardner, E. (2019). Deprescribing in end-of-life care. British
Journal of Community Nursing, 24(10), 474–477. https://doiorg.ezproxy.mnsu.edu/10.12968/bjcn.2019.24.10.474
Garfinkel, D. (2018). Poly-de-prescribing to treat
polypharmacy: Efficacy and safety. Therapeutic Advances in
Drug Safety, 9(1), 25-43.
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1177/20420986177
36192

Included or
Excluded and
Document

Rationale

Excluded

Case study on when to consider palliative
care

Excluded

Not pertaining to subject, instead
discusses medical marijuana

Excluded

The aim of study was to collect data on
proportion of patients in hospice with
cystic fibrosis taking antifibrotics and the
side effects that would be described and
obstacles to deprescribing
Discusses types of palliative care patients
benefit from medication management
services

Excluded

Included

Examined the effect of using a
deprescribing tool to medication regimen
for older adults

Excluded

Discusses the pharmacists role in
improving patient outcomes with
medication use deprescribing

Excluded

Article revolves around mirtazapine’s
safety and effectiveness of treating cancer
symptoms

Excluded

Focused on assessing drug interactions at
end of life without addressing health
related outcomes or quality of life

Included

Reviews medications that should be
stopped at the end of life

Excluded

Describes the efficacy and safety of
deprescribing in older adults and
excluded patients with limited life
expectancy
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Document

Garfinkel, D. (2019). Poly-de-prescribing vs polypharmacy the weapon to fight an iatrogenic epidemic: An overview.
European Journal of Geriatrics and Gerontology, 1(1), 1-10.
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.4274/ejgg.galenos.2
019.14
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Kierner, K., Weixler, D., Masel, E., Gartner, V., Watzke, H.,
Kierner, K. A., Masel, E. K., & Watzke, H. H. (2016).
Polypharmacy in the terminal stage of cancer. Supportive Care
in Cancer, 24(5), 2067–2074. https://doiorg.ezproxy.mnsu.edu/10.1007/s00520-015-3007-z
Kolovetsios, M., & Yones, H. (2018). P-206 The role and
impact of pharmacists within a hospice’s care home support
team. BMJ Supportive & Palliative Care, 8
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare2018-hospiceabs.231
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Fairclough, D., Hanson, L., LeBlanc, T., Samsa, G., Wolf, S.,
Aziz, N., Currow, D., Ferrell, B., Wagner-Johnston, N., Zafar,
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(2015). Safety and Benefit of Discontinuing Statin Therapy in
the Setting of Advanced, Life-Limiting Illness: A Randomized
Clinical Trial. JAMA Internal Medicine, 175(5), 691–700.
https://doi.org/10.1001/jamainternmed.2015.0289
LeBlanc, T. W., McNeil, M. J., Kamal, A. H., Currow, D. C.,
& Abernethy, A. P. (2015). Polypharmacy in patients with
advanced cancer and the role of medication discontinuation.
Lancet Oncology, 16(7), e333-e341.
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Lindsay, J., Dooley, M., Martin, J., Fay, M., Kearney, A., &
Barras, M. (2014). Reducing potentially inappropriate
medications in palliative cancer patients: Evidence to support
deprescribing approaches. Supportive Care in Cancer, 22(4),
1113-9.
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Marin, H., Mayo, P., Thai, V., Dersch-Mills, D., Ling, S.,
Folkman, F., & Chambers, C. (2020). The impact of palliative
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McNulty, J. P., & Muller, G. (2014). Compounded drugs of
value in outpatient hospice and palliative care practice.
International Journal of Pharmaceutical Compounding, 18(3),
190-200. Retrieved from
http://ezproxy.mnsu.edu/login?url=https://www-proquestcom.ezproxy.mnsu.edu/docview/1611612423?accountid=1225
9
Parekh, N., Good, C. B., Neilson, L., Shrank, W. H., &
Schenker, Y. (2019). Deprescribing in Advanced Illness:

Included

Rationale

Review on deprescribing, discussing
factors of barriers and enabling its
implementation, attitudes of patients and
providers and recommendations from the
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analyzes the difference between the
medications
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medication reviews using specific
guidelines
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to the palliative care consult vs after the
PCC; Examines association of
inappropriate medications and goals of
care
Discusses common compounds used in
outpatient hospice and palliative care to
treat common conditions

Excluded

Excluded

Addresses barrier for deprescribing and
proposes action steps

33
Reference
(Include the full reference here)
Aligning Patient, Clinician, and Health Plan Goals. JGIM:
Journal of General Internal Medicine, 34(4), 631–633.
https://doi-org.ezproxy.mnsu.edu/10.1007/s11606-019-048457
Parker, K., Bull-Engelstad, I., Benth, J., Aasebø, W., von der
Lippe, N., Reier-Nilsen, M., Os, I., & Stavem, K. (2019).
Effectiveness of using STOPP/START criteria to identify
potentially inappropriate medication in people aged ≥ 65 years
with chronic kidney disease: a randomized clinical trial.
European Journal of Clinical Pharmacology, 75(11), 1503–
1511. https://doi.org/10.1007/s00228-019-02727-9
Paque, K., Elseviers, M., Vander Stichele, R., Pardon, K.,
Vinkeroye, C., Deliens, L., Christiaens, T., & Dilles, T.
(2019). Balancing medication use in nursing home residents
with life-limiting disease. European Journal of Clinical
Pharmacology, 75(7), 969–977. https://doiorg.ezproxy.mnsu.edu/10.1007/s00228-019-02649-6
Parsons C, Hughes CM, Passmore AP, & Lapane KL. (2010).
Withholding, discontinuing and withdrawing medications in
dementia patients at the end of life: a neglected problem in the
disadvantaged dying? Drugs & Aging, 27(6), 435–449.
https://doi-org.ezproxy.mnsu.edu/10.2165/11536760000000000-00000
Prabhu, A., Sutherland, A., Bradley, V., & Pegrum, H. (2017).
P-99 the use of an oncological palliative deprescribing
guideline to aid rationalising medications in patients in the last
six months of life. BMJ Supportive & Palliative Care, 7
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare2017-00133.98
Schenker, Y., Kavalieratos, D., Resick, J., Park, S. Y., Jeong,
K., Pruskowski, J., Abernethy, A., & Kutner, J. S. (2019).
Associations Between Polypharmacy, Symptom Burden, and
Quality of Life in Patients with Advanced, Life-Limiting
Illness. JGIM: Journal of General Internal Medicine, 34(4),
559–566. https://doi-org.ezproxy.mnsu.edu/10.1007/s11606019-04837-7
Shrestha, S., Poudel, A., Steadman, K., & Nissen, L. (2020).
Outcomes of deprescribing interventions in older patients with
life‐limiting illness and limited life expectancy: A systematic
review. British Journal of Clinical Pharmacology, 86(10),
1931–1945. https://doiorg.ezproxy.mnsu.edu/10.1111/bcp.14113
Takahashi, M., Maeda, K., & Wakabayashi, H. (2018).
Prevalence of sarcopenia and association with oral health‐
related quality of life and oral health status in older dental
clinic outpatients. Geriatrics & Gerontology International,
18(6), 915–921. https://doiorg.ezproxy.mnsu.edu/10.1111/ggi.13279
Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of
Deprescribing Interventions in Older Hospitalised Patients on
Prescribing and Clinical Outcomes: A Systematic Review of

Included or
Excluded and
Document

Rationale

Included

Identified potentially inappropriate
prescriptions and potential prescribing
omissions using a deprescribing tool and
determined the effect on medication
adherence and qol

Excluded

Study that examines deprescription and
prevalence in a nursing home

Excluded

Addresses research surrounding end of
life patient care of patients and the
discontinuation of medications by
physicians

Excluded

Study aimed at reviewing the use of a
deprescribing tool available in the EHR

Included

Synthesis of evidence in adults with
advanced illness and the impact that more
medications has on symptom burden and
quality of life

Included

Investigates the outcomes of
deprescribing in the older patients with
limited life expectancy

Exclude

Discussion of oral health related quality
of life and sarcopenia

Excluded

Examine the efficacy of deprescribing
intervention in reducing PIMs and clinical
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General Internal Medicine, 34(10), 2029–2037. https://doiorg.ezproxy.mnsu.edu/10.1007/s11606-019-05152-x

Included or
Excluded and
Document

Excluded

Rationale

health outcomes; Participants did not fit
in the categories of end of life
Patient, caregiver, and healthcare
provider’s experience with medication
use with life limiting illness

Excluded

Article aims at quantifying number of
patients with polypharmacy in hospice
setting and consider adding a describing
tool

Excluded

Article provides direct reference on
guidelines on prescribing antiepileptic
drugs in palliative care

Excluded

Evaluating the frequency and factors for
continuation of medications that have
limited benefit after being admitted to
hospice
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Curtin, D., Jennings, E., Daunt,
R., Curtin, S., Randles, M.,
Gallagher, P., & O’Mahony, D.
(2020). Deprescribing in Older
People Approaching End of Life:
A Randomized Controlled Trial
Using STOPPFrail Criteria.
Journal of the American
Geriatrics Society, 68(4), 762–
769. https://doiorg.ezproxy.mnsu.edu/10.1111/jg
s.16278

Examine the
effect of the
application of
a
deprescribing
tool to
medication
regimens of
older adults
with limited
life
expectancy

N=130, adults
75+yo with
and limited
life
expectancy
polypharmacy
/Two hospitals
in Ireland

Randomized
Control
Trial/Level 2

Intervention
group-65; Control
group=65/STOPP
Frail‐guided
deprescribing tool

Measure of the
primary outcome
including the change
in number of
medications at 3
months and secondary
outcomes including
unscheduled hospital
presentations, falls,
quality of life, monthly
medication costs, and
mortality

-Application of STOPPFrail
criteria resulted in significant
reduction in polypharmacy and
monthly medication costs

-Strength of the study included
patients with dementia which this
population group is typically
excluded
-Larger scale trial with greater
statistical abilities is required to
provide evidence for clinicians that
using the STOPPFrail to deprescribe
medications can be achieved without
compromising clinical outcomes

Gardner, E. (2019). Deprescribing
in end-of-life care. British Journal
of Community Nursing, 24(10),
474–477. https://doiorg.ezproxy.mnsu.edu/10.12968/b
jcn.2019.24.10.474

The aim is to
address
polypharmacy
within end-oflife care

N/a

Expert
Opinion/Level 5

N/a

N/a

- Within end-of-life medication
management, each drug needs
to be divided into nonessential
and essential groups

Kierner, K., Weixler, D., Masel,
E., Gartner, V., Watzke, H.,
Kierner, K. A., Masel, E. K., &
Watzke, H. H. (2016).
Polypharmacy in the terminal
stage of cancer. Supportive Care
in Cancer, 24(5), 2067–2074.

Determine
number of
patients
receiving
polypharmacy
at the end of
life with

-No significant differences
were noted in the health-related
outcomes including quality of
life although as noted that the
study was underpowered to
detect significant changes in
these outcomes

-Initiation of medicines is
guideline-driven, but guidance
regarding when it may be safe
or appropriate to discontinue
treatment is less prevalent

Patients that
had passed
away with
advanced
cancer
between
January 2011-

Retrospective,
longitudinal,
single cohort
study/Level 4

Sociodemographic
, disease-related,
and medical
variables were
retrieved

-Sociodemographic
and medications were
collected at each
predefined time period
-Medication
prescriptions were

-9 days prior to death,
polypharmacy was registered
in 95% of patients
-Prescriptions for 11 different
medications/day

- Nurse medical prescribers need to
carefully consider the therapeutic
benefits of continuing medication as
well as the risks of deprescribing at
the end of life.
- The aim would be to improve
patients’ quality of life by reducing
their drug burden
-It is imperative that discussions
about medication
management occur promptly and
throughout the dying
process, involving the patient at all
times
-First detailed analysis of the
quantity composition and course of
medical therapy in terminal ill
patients
-Further projects should be focused
on drug-drug interactions and impact
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0520-015-3007-z

advanced
cancer and
look at the
difference of
medications
between
hospice and
palliative care
wards

March
2013/N=100
patient
charts/Two
specialized
wards, hospice
and palliative
care at
University
Hospital of
Vienna

Design/ Level of
Evidence
(Melnyk &
FineoutOverholt, 2015)
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-Drugs were
categorized into
classes

determined at four
predefined time points
9, 6, 3, 0 days before
death

-The number dropped
significantly on the last day as
many 61% of patients were still
taking more than 4 drugs

of polypharmacy on the patient’s
quality of life
-Recommended for more controlled
trials with structured programs will
be needed to reduce quantity of
medications and generate scientific
evidence on discontinuation of
medication in terminally ill cancer
patients

-Drugs that were
prescribed for the
day of assessment
along were
considered acute
medication
whereas drugs
prescribed earlier
than 1 day before
or after were
considered chronic
medications

-No difference was noted
between the oncology and
palliative ward
-polypharmacy was dependent
on the patients’ ECOG
performance status, type of
ward, number of day before
death and age

-Polypharmacy
was defined as 5
or more drugs/day

Kutner, J., Blatchford, P., Taylor,
D., Ritchie, C., Bull, J.,
Fairclough, D., Hanson, L.,
LeBlanc, T., Samsa, G., Wolf, S.,
Aziz, N., Currow, D., Ferrell, B.,
Wagner-Johnston, N., Zafar, S.,
Cleary, J., Dev, S., Goode, P.,
Kamal, A., … Abernethy, A.
(2015). Safety and Benefit of
Discontinuing Statin Therapy in
the Setting of Advanced, LifeLimiting Illness: A Randomized
Clinical Trial. JAMA Internal
Medicine, 175(5), 691–700.
https://doi.org/10.1001/jamaintern
med.2015.0289

Evaluate
safety,
clinical, and
cost impact of
discontinuing
statin
medications in
palliative care
setting

Limited life
expectancy in
adults older
than 18 years
of
age/N=381/Pa
lliative care

Randomized
control
trial/Level 2

-n=189
intervention;
n=192 control
-Primary outcome:
Death within 60
days
Secondary
outcomes:
survival,
cardiovascular
events,
performance
status, qol,
symptoms,
number of
nonstatin

-Up to 12 months
-Discontinuation of
stain on the basis of
randomization in
coordination of
clinical research
coordinator with
physician or primary
care provider

-Proportion of patients that
died within 60 days did not
have a significant difference
between the groups
-QOL was better in the
interventional group
-13 participants in intervention
group and 11 participants in the
control group experienced
cardiovascular event
-Cost savings $3.37 per day
and $716 per patient

-Evidence that deprescribing statins
do not affect survival when
prescribed for primary or secondary
prevention of cardiovascular disease
-Cost savings
-May improve QOL
-Merits patient and provider
discussion to continue or stop
therapy with statin medications
-Future research to explore use of
other medications in populations
with limited life expectamcy
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n/a

-Polypharmacy is prevalent in
the advanced cancer population
with mean of 3-9.1 prescribed
drugs and older patients often
had more prescribed drugs

-Need a balance of medication
usefulness and burden of adverse
effects
--Adverse effects include poor
concentration, reduced quality of life
and worsening physical functioning

medications, and
cost savings
-McGill to
measure QOL
-Edmonton
Symptom
Assessment
System Scale to
measure symptom
LeBlanc, T. W., McNeil, M. J.,
Kamal, A. H., Currow, D. C., &
Abernethy, A. P. (2015).
Polypharmacy in patients with
advanced cancer and the role of
medication discontinuation.
Lancet Oncology, 16(7), e333e341.
doi:http://dx.doi.org.ezproxy.mns
u.edu/10.1016/S14702045(15)00080-7

Lindsay, J., Dooley, M., Martin,
J., Fay, M., Kearney, A., &
Barras, M. (2014). Reducing
potentially inappropriate
medications in palliative cancer
patients: Evidence to support
deprescribing approaches.

Examines the
existing
literature on
polypharmacy
in advanced
cancer and
end-of-life
settings by
reviewing
evidencebased
approaches to
reduce
polypharmacy
, and outlining
the potential
benefits of
decreasing the
number of
drugs

N=22 articles
addressing
polypharmacy
frequency, the
amount of
inappropriate
medications
and symptom
burden, and
interventions
to reduce
polypharmacy

Evaluates the
evidence to
assess the
outcomes and
potential
methods used
for identifying

N=51 articles
assessed
initially

Systematic
Review/Level I

n/a

-Much of the drugs prescribed
were for long term chronic care
management
-End of life approaches,
increase in prescribed drugs
-Anticholinergic drugs are
often increased at end of life
and is associated with adverse
effects

-Inadequate attention given to drugs
that are prescribed for comorbidities
and long term complications
-Define and screen for polypharmacy
in advanced cancer populations

-When inappropriate
medications were discontinued,
a reduction of mortality existed
Systematic
Review/Level 1

N/a

N/a

-Evidence of incidences of
polypharmacy and PIMs in
geriatric
- No interventional, follow-up
or randomized controlled trials
have been performed in

-Arguably in the article, it is stated
that “all medications are assumed
inappropriate until they improve
symptom control or quality of life”
-Prior to designing and implementing
programs for deprescription,
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and ceasing
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palliative
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palliative cancer patients,
demonstrating that while PIMs
exist in this population, there is
no evidence of benefits of
ceasing medications

quantitative data on health outcomes
should be obtained

- Ceasing PIMs in geriatric
patients lead to an
improvement in health with no
major adverse effects reported
-Cost analysis have shown that
the incidence of PIMs
contributes a significant burden
to the healthcare system

Parker, K., Bull-Engelstad, I.,
Benth, J., Aasebø, W., von der
Lippe, N., Reier-Nilsen, M., Os,
I., & Stavem, K. (2019).
Effectiveness of using
STOPP/START criteria to
identify potentially inappropriate
medication in people aged ≥ 65
years with chronic kidney
disease: a randomized clinical
trial. European Journal of Clinical
Pharmacology, 75(11), 1503–
1511.
https://doi.org/10.1007/s00228019-02727-9

Identifies
potentially
inappropriate
prescriptions
and potential
prescribing
omissions
using a
deprescribing
tool and
determined
effect on
medication
adherence and
qol

Older adults
over the age
of 65 years
with CKD end
stage
5/N=180/Nep
hrology
centers

Randomized
control
trial/Level 2

-STOPP/START
criteria for
medication review
-Morisky
Medication
Adherence Saale
to assess
medication
adherence
-Short Form
Health Survey to
assess HRQOL

-Interventions
completed at baseline
and at 6 month follow
up

-Patients with one or more PIPs
decreased in the intervention
group whereas in the control
group, it remained the same
-Probability of PIPs didn’t
differ between the groups but
the PPOs were lower in the
intervention group
-At 6 months, no difference
between the groups of
medication adherence
-No significant different in
average number of medications
or HRQol at followup
-PIMs identified were
preventative medications or
medications that had no
therapeutic effects in advanced
CKD

-Limitation of study was criteria in
patients with advanced CKD is not
known
-Screening tool for medication
review can initiate dialog between
those involved with medications and
with the patient
-Further research on finding ways to
evaluate impact on medication
adherence and the HRQoL
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-ACE inhibitor was the most
common medication ommitted
Schenker, Y., Kavalieratos, D.,
Resick, J., Park, S. Y., Jeong, K.,
Pruskowski, J., Abernethy, A., &
Kutner, J. S. (2019). Associations
Between Polypharmacy,
Symptom Burden, and Quality of
Life in Patients with Advanced,
Life-Limiting Illness. JGIM:
Journal of General Internal
Medicine, 34(4), 559–566.
https://doiorg.ezproxy.mnsu.edu/10.1007/s1
1606-019-04837-7

Evaluate
associations
between
polypharmacy
, symptom
burden, and
quality of life
(QOL) in
patients with
advanced, lifelimiting
illness

N=372
participants
that are adults
with
advanced, life
limiting
illness
enrolled in
palliative care
from 15 sites
in U.S.A

Secondary
analysis of data
from a large,
multi-center
randomized
clinical
trial/Level 4

Measures
collected at
baseline
Medications were
assessed by
documenting the
number of
prescriptions and
OTC
Symptom burden
was assessed by
administering the
Edmonton
Symptom
Assessment Scale
Quality of Life
was measured
using the McGill
Quality of Life
Questionnaire
Participant
characteristics
included
demographics,
primary diagnosis,
Charlson
Comorbidity Index
score,
performance
status, and
enrollment in
hospice.

Polypharmacy groups
were defined as low
(0–8 medications),
medium (9–13
medications), and high
(≥14 medications)
Statistical analysis
with descriptive
statistics using
STATA

-Polypharmacy in adults with
life limited illness is associated
with higher burden of
symptoms and lower quality of
life
-Suggests worsening quality of
life is attributed to the
worsening symptoms
associated with medications
-Significant medication burden
placed on patients near the end
of life warrants careful
consideration

-Significant medication burden
placed on patients at the end of life
warrants careful consideration
-Future research for deprescribing
strategies to reduce the use of
inappropriate medications and
implementing and evaluating these
strategies
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Shrestha, S., Poudel, A.,
Steadman, K., & Nissen, L.
(2020). Outcomes of
deprescribing interventions in
older patients with life‐limiting
illness and limited life
expectancy: A systematic review.
British Journal of Clinical
Pharmacology, 86(10), 1931–
1945. https://doiorg.ezproxy.mnsu.edu/10.1111/bc
p.14113

Investigate the
evidence for
outcomes of
deprescribing
interventions
in older
patients with
limited life
expectancy or
illness

N=9 articles
(n=1375
participants)

Systematic
Review/Level I

n/a

-Primary outcome is
medication
appropriateness

-One review stated that
deprescribing intervention
reduced the symptoms and side
effects related to polypharmacy

-When studying clinical outcomes, it
is important to consider the illness
progression and patient
characteristics such as age, their
disease patterns and settings during
deprescribing.
More evidence is needed on the
clinical impact of deprescribing and
the effect on other areas including
physical, cognitive and psychosocial

-Secondary outcome is
clinical outcomes and
cost

-With deprescribing
interventions, medicine related
harms were reduced
-Deprescribing may not
accelerate death in patient with
palliative care
-QOL is high priority with
patient and caregivers. Effect
of deprescribing on QOL was
found to be inconsistent.
-Additional outcomes including
cost savings associated with
deprescribing and sleep quality,
bowel function, cognitive
function, physical function,
general health, performance
and symptoms were also
reported but changes in the
intervention group were not
significantly

